Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -53.81% | -80.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.81% | -80.35% | |||
| Cost of Revenue | -74.12% | 446.03% | |||
| Gross Profit | 89.72% | -97.49% | |||
| SG&A Expenses | -15.27% | -33.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.17% | -45.55% | |||
| Operating Income | -52.72% | -175.15% | |||
| Income Before Tax | 20.33% | -278.87% | |||
| Income Tax Expenses | -100.00% | 833.33% | |||
| Earnings from Continuing Operations | 20.85% | -280.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.85% | -280.27% | |||
| EBIT | -52.72% | -175.15% | |||
| EBITDA | -36.88% | -156.83% | |||
| EPS Basic | 21.15% | -262.08% | |||
| Normalized Basic EPS | -46.76% | -197.61% | |||
| EPS Diluted | 21.84% | -268.42% | |||
| Normalized Diluted EPS | -46.76% | -198.49% | |||
| Average Basic Shares Outstanding | 0.42% | 11.21% | |||
| Average Diluted Shares Outstanding | 0.42% | 10.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||